Tumor size reduction after each phase of R-HDS program. Patients were re-evaluated before the start of each of the 4 high-dose chemotherapy cycles. All phases were followed by a measurable tumor size reduction with CR in 50% of patients after high-dose cytarabine (HD-Ara-C) and 50% after the final myeloablative phase(s). p-STD indicates after standard dose chemotherapy; p-CTX, after high-dose cyclophosphamide; p-AraC, after high-dose cytarabine; and p-Mel/Mito-Mel, after high-dose melphalan and after high-dose mitoxantrone/melphalan.